Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction

British Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2009, Pages 43-46

  Kim, Tae Eun ^a   Kim, Bo Hyung ^a   Kim, Jung Ryul ^a   Lim, Kyoung Soo ^a   Hong, Jang Hee ^b   Kim, Kyu Pyo ^a   Kim, Hwa Sook ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Food; Pharmacokinetics; Phosphodiesterase type 5 inhibitor; Udenafil

Indexed keywords

UDENAFIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ERECTILE DYSFUNCTION; FAT INTAKE; FOOD DRUG INTERACTION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AREA UNDER CURVE; CROSS-OVER STUDIES; ERECTILE DYSFUNCTION; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINES; YOUNG ADULT;

EID: 67650931603     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03404.x     Document Type: Article

References (10)

1. Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharmacal Res 2002 25 : 873 8.
2. Pfizer, Inc. Viagra package insert New York : Pfizer, Inc, 2006. Available at http://www.fda.gov/cder/foi/label/2008/020895s026lbl.pdf (last accessed 14 March 2009).
3. Bayer Pharmaceuticals Corp. Levitra package insert Leverkusen : Bayer Pharmaceuticals Corp, 2007. Available at http://www.fda.gov/cder/foi/label/2008/ 021400s011lbl.pdf (last accessed 14 March 2009).
4. Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, Cho JY, Yu KS, Shin SG, Paick JS, Jang IJ. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008 65 : 848 54.
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, MD : US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2002. Available at http://www.fda.gov/cder/guidance/ 5194fnl.pdf (last accessed 14 March 2009).
6. Korean National Institute of Toxicological Research. Guideline on Food-Effect Bioavailability and Fed Bioequivalence Studies. Seoul : Korean National Institute of Toxicological Research, 2005. Available at http://kfda.go.kr/index2.html (last accessed 14 March 2009).
7. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Rockville, MD : US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001. Available at http://www.fda.gov/cder/guidance/ 3616fnl.pdf (last accessed 14 March 2009).
8. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999 37 : 213 55.
9. Dong-A Pharmceutical Company. Zydena® (udenafil). Investigator's Brochure (Study Number: DA8159DIFI).
10. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh JK, Kim SC. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008 5 : 946 53.